Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24496722 | 0.90 | KMT2A (0.46) | GAACRHBPCRHR2SMN1; SMN2CASP1 | |
| SCHEMBL24916517 | 0.90 | CASP1 (0.41) | GAASMN1; SMN2CASP1MEN1KMT2A | |
| SCHEMBL23943671 | 0.90 | CASP1 (0.41) | GAASMN1; SMN2CASP1MEN1KMT2A | |
| SCHEMBL24496736 | 0.88 | CASP1 (0.44) | GAASMN1; SMN2CASP1MEN1KMT2A | |
| SCHEMBL22854050 | 0.88 | CASP1 (0.44) | GAASMN1; SMN2CASP1MEN1KMT2A | |
| SCHEMBL26445000 | 0.88 | GAA (0.39) | GAAMAPTCRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL22746497 | 0.87 | GAA (0.46) | GAAMAPTCRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL22336342 | 0.87 | GAA (0.46) | GAAMAPTCRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL21649720 | 0.87 | GAA (0.46) | GAAMAPTCRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL22336344 | 0.87 | GAA (0.46) | GAAMAPTCRHBPCRHR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135930-A1 | AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135930-A1 | AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF | MYADM, FUT7, SIGLEC7 | GAA 607/4885MAPT 3581/4885CRHBP 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.